Healthcare / Medical DevicesNYSE American
$0.17
+0.02 (+13.78%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 22%
FCF escenarios
weak_data · normalized FCF $-11.9M · quality 61.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
11/100
F
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$16M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-712.6%
↓Gross Margin
-4.1%
↓Debt/Equity
1.84
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+6.3%
FCF CAGR
—
FCF margin
-317.3%
FCF / Net income
0.58x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $4.9M · net income $-27.0M · FCF $-15.7M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $4.9M | $4.9M | $4.4M | $5.0M | $4.1M |
| Net Income | $-27.0M | $-27.0M | $-21.1M | $-15.6M | $-11.2M |
| EBITDA | $-21.1M | $-21.1M | $-17.5M | $-14.8M | $-10.6M |
| EPS | -0.75 | -0.75 | -0.33 | -0.25 | -0.18 |
| Gross Margin | -4.1% | -4.1% | -2.6% | -45.8% | -121.3% |
| Operating Margin | -268.4% | -268.4% | -312.3% | -307.4% | -269.1% |
| Net Margin | -546.6% | -546.6% | -479.5% | -308.7% | -271.5% |
| Balance Sheet | |||||
| Debt/Equity | 1.84 | 1.84 | -0.88 | -2.65 | 0.17 |
| Current Ratio | 0.75 | 0.75 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-15.7M | $-15.7M | $-11.9M | $-10.6M | $-10.8M |
| Returns | |||||
| ROE | -712.6% | -712.6% | 88.7% | 438.3% | -98.2% |
| Valuation | |||||
| P/B | 1.61 | 1.61 | — | — | — |
| Growth & Yield | |||||
| Revenue Growth | 12.5% | 12.5% | -12.9% | 22.6% | — |
| EPS Growth | -127.7% | -127.7% | -31.9% | -42.1% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-96.3%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.33 → -0.75
Residual
-96.3%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.